Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-bridge Cycle01:26

Cross-bridge Cycle

As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment.

Journal of medical economics·2023
Same author

Initial gene vector dosing for studying symptomatology of amyotrophic lateral sclerosis in non-human primates.

Journal of medical primatology·2015
Same author

Administration of glucocorticoids in boys with Duchenne muscular dystrophy.

Continuum (Minneapolis, Minn.)·2013
Same author

How to explore a patient with a chronic axonal polyneuropathy.

Handbook of clinical neurology·2013
Same author

Management of symptoms in amyotrophic lateral sclerosis.

Current treatment options in neurology·2008
Same author

Serial electrophysiologic studies in rhesus monkeys with Krabbe disease.

Muscle & nerve·2005

Related Experiment Video

Updated: Jun 25, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

Neuralgic amyotrophy.

Lenay Santana1, Amparo Gutierrez

  • 1Amparo Gutierrez, MD Department of Neurology, Louisiana State University Health Science Center, 1542 Tulane Avenue, New Orleans, LA 70112, USA. agutie@lsuhsc.edu.

Current Treatment Options in Neurology
|February 13, 2009
PubMed
Summary

Neuralgic amyotrophy presents diversely, affecting nerves beyond the plexus. While typically benign, disabling pain may require treatment, with short-term steroids considered an option.

Area of Science:

  • Neurology
  • Clinical Medicine

Background:

  • Neuralgic amyotrophy (NA) exhibits diverse clinical manifestations, extending beyond initial descriptions as a plexopathy.
  • NA can involve isolated sensory or cranial nerves, highlighting its varied presentation.
  • Despite a generally benign prognosis and good recovery, neuropathic pain is a significant and disabling symptom.

Purpose of the Study:

  • To explore the clinical spectrum of neuralgic amyotrophy.
  • To evaluate treatment options for neuropathic pain associated with NA.
  • To assess the potential role of corticosteroids in managing NA.

Main Methods:

  • Review of clinical presentations of neuralgic amyotrophy.
  • Analysis of current treatment strategies for neuropathic pain.
  • Evaluation of the evidence for corticosteroid use in NA.

More Related Videos

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
10:49

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury

Published on: September 18, 2011

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
06:35

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

Published on: June 15, 2018

Related Experiment Videos

Last Updated: Jun 25, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
10:49

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury

Published on: September 18, 2011

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
06:35

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

Published on: June 15, 2018

Main Results:

  • Neuralgic amyotrophy demonstrates a wide range of clinical presentations, including isolated nerve involvement.
  • Non-steroidal anti-inflammatory drugs (NSAIDs) and short-term narcotics are standard treatments for pain.
  • Evidence regarding the impact of corticosteroids on disease duration and pain is limited.

Conclusions:

  • Short-term corticosteroid therapy may be a viable treatment option for neuralgic amyotrophy patients due to low cost and minimal adverse effects.
  • Further research is needed to establish the efficacy of corticosteroids in NA treatment.
  • Management should focus on addressing the disabling neuropathic pain characteristic of the condition.